Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Vlad Malkov"'
Autor:
Alexandra Beilina, Luis Bonet-Ponce, Ravindran Kumaran, Jennifer J. Kordich, Morié Ishida, Adamantios Mamais, Alice Kaganovich, Sara Saez-Atienzar, David C. Gershlick, Dorien A. Roosen, Laura Pellegrini, Vlad Malkov, Matthew J. Fell, Kirsten Harvey, Juan S. Bonifacino, Darren J. Moore, Mark R. Cookson
Publikováno v:
Cell Reports, Vol 31, Iss 5, Pp - (2020)
Summary: Mutations in Leucine-rich repeat kinase 2 (LRRK2) cause Parkinson’s disease (PD). However, the precise function of LRRK2 remains unclear. We report an interaction between LRRK2 and VPS52, a subunit of the Golgi-associated retrograde protei
Externí odkaz:
https://doaj.org/article/8f3645a2b68b47bab2889e3c6b78354d
Autor:
Cate Speake, Alexander Pichugin, Tejram Sahu, Vlad Malkov, Robert Morrison, Ying Pei, Laure Juompan, Neta Milman, Stasya Zarling, Charles Anderson, Sharon Wong-Madden, Jason Wendler, Andrew Ishizuka, Zachary W MacMillen, Valentino Garcia, Stefan H I Kappe, Urszula Krzych, Patrick E Duffy
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159449 (2016)
Malaria vaccine development has been hampered by the limited availability of antigens identified through conventional discovery approaches, and improvements are needed to enhance the efficacy of the leading vaccine candidate RTS,S that targets the ci
Externí odkaz:
https://doaj.org/article/857fab6995cb463fbc79815eb890ea8f
Autor:
Jim Weatherall, Khader Shameer, Faisal Khan, Youyi Zhang, Sreenath Nampally, Emmette Hutchison, Vlad Malkov, Imran Khan Anwer Neelufer
The amount of time and resources invested in bringing novel therapeutics to market has increased year over year with fewer successful treatments reaching patients. In the lifecycle of drug development, the clinical phase is a major contributor to thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::419d3b19e2a041f703ebb01effe2a3dc
https://doi.org/10.1101/2021.11.12.21266277
https://doi.org/10.1101/2021.11.12.21266277
Autor:
David C. Gershlick, Morié Ishida, Dorien A. Roosen, Vlad Malkov, Luis Bonet-Ponce, Ravindran Kumaran, Matthew J. Fell, Alexandra Beilina, Alice Kaganovich, Kirsten Harvey, Jennifer J. Kordich, Juan S. Bonifacino, Sara Saez-Atienzar, Darren J. Moore, Laura Pellegrini, Adamantios Mamais, Mark R. Cookson
Publikováno v:
Cell reports
Cell Reports, Vol 31, Iss 5, Pp-(2020)
Cell Reports, Vol 31, Iss 5, Pp-(2020)
SUMMARY Mutations in Leucine-rich repeat kinase 2 (LRRK2) cause Parkinson’s disease (PD). However, the precise function of LRRK2 remains unclear. We report an interaction between LRRK2 and VPS52, a subunit of the Golgi-associated retrograde protein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c67523bc1f6525e34d67f472f390c442
https://pubmed.ncbi.nlm.nih.gov/32375042
https://pubmed.ncbi.nlm.nih.gov/32375042